

Methotrexate In Psoriatic Arthritis

Submission date 04/02/2002	Recruitment status No longer recruiting	☒ Prospectively registered ☐ Protocol
Registration date 04/02/2002	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 23/02/2012	Condition category Musculoskeletal Diseases	☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Gabrielle Kingsley

Contact details

Rheumatology Unit
GKT School of Medicine
5th Floor, Thomas Guy House
Guy's Campus
St Thomas Street
London
United Kingdom
SE1 9RT
+44 (0)20 7995 4394
gabrielle.kingsley@kcl.ac.uk

Additional identifiers

Protocol serial number

K0561

Study information

Scientific Title

Acronym

MIPA

Study objectives

Psoriatic arthritis is a type of arthritis, which is often relatively mild and does not cause severe inflammation or long-term damage to joints. As a consequence many patients only need anti-inflammatory drugs and steroid injections into their joints. There is evidence that some patients with psoriatic arthritis have a more severe disease. They can become quite disabled and their joints damaged. As a consequence rheumatologists are keen to treat patients with more severe disease with disease modifying drugs, in particular a drug called methotrexate. This is the most effective drug of its class when used to treat rheumatoid arthritis. It also improves the skin in psoriasis. At present there is insufficient evidence that it works in psoriatic arthritis. The purpose of this study is to determine whether treatment with methotrexate is effective in psoriatic arthritis. It will determine if methotrexate reduces disease activity and improves function in patients whose disease is severe enough for their rheumatologist to consider using a disease modifying drug. The MIPA study will compare the effect of methotrexate against a placebo in patients with psoriatic arthritis. The trial will assess their function over six months.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Psoriatic arthritis

Interventions

Patients will be randomised to methotrexate or placebo.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Methotrexate

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

31/10/2008

Eligibility

Key inclusion criteria

Patients with psoriatic arthritis currently attending specialist rheumatology clinics and with active peripheral synovitis.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

30/04/2002

Date of final enrolment

31/10/2008

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Rheumatology Unit

London

United Kingdom

SE1 9RT

Sponsor information

Organisation

Arthritis Research Campaign (ARC) (UK)

ROR

<https://ror.org/02jkpm469>

Funder(s)

Funder type

Charity

Funder Name

Arthritis Research Campaign (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2012		Yes	No
Other publications	current concepts and new developments	01/10/2003		Yes	No